Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q2 EPS Loss of $0.08
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q2 EPS of ($0.08), $0.03 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $200 thousand versus the consensus estimate of $190 thousand.